MedTrace Logo

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

NCT00878293 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-07-15

No results posted yet for this study

Summary

The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.

Conditions

  • Diabetic Polyneuropathy

Interventions

DRUG

GRT6005

liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

DRUG

MS Continus®

60 mg, capsule, once daily

DRUG

Placebo

liquid formulation and capsule, once daily

Sponsors & Collaborators

  • Tris Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Forst, Prof. Dr. med · IKFE, Parcusstr. 8, 55116 Mainz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878293 on ClinicalTrials.gov